| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -65,340 | -44,947 |
| Stock-based compensation expense | 9,159 | 6,149 |
| Depreciation | 4,017 | 2,693 |
| Loss on fixed assets write-off | 181 | 181 |
| Non-cash lease expense | 3,936 | 2,664 |
| Accretion of premiums and discounts on available-for-sale marketable securities | 2,530 | 1,825 |
| Amortization of non-cash collaboration revenue | 212 | 87 |
| Income tax payable | - | 0 |
| Change in fair value of long-term investments | 1,292 | 1,292 |
| Accounts receivable | -297 | -384 |
| Prepaid expenses and other assets | -3,827 | -2,687 |
| Accounts payable | 708 | 2,284 |
| Deferred revenue and collaboration advance | -17,991 | -10,417 |
| Accrued expenses and other current liabilities | 1,547 | -2,476 |
| Operating lease liabilities | -4,146 | -2,818 |
| Other non-current liabilities | -91 | 143 |
| Net cash used in operating activities | -65,346 | -44,093 |
| Purchases of property and equipment | 489 | 415 |
| Proceeds from sale of property and equipment | 37 | 37 |
| Purchases of available-for-sale marketable securities | 46,859 | 40,796 |
| Maturities of available-for-sale marketable securities | 118,474 | 84,974 |
| Net cash provided by (used in) investing activities | 71,163 | 43,800 |
| Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs | - | 0 |
| Proceeds from issuance of common stock under the equity incentive plan and espp | 109 | - |
| Payment of deferred financing costs | 539 | 352 |
| Proceeds from issuance of common stock under espp | - | 109 |
| Net cash provided by (used in) financing activities | -430 | -243 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 5,387 | -536 |
| Cash and cash equivalents at beginning of period | 32,634 | - |
| Cash and cash equivalents at end of period | 38,021 | - |
Metagenomi, Inc. (MGX)
Metagenomi, Inc. (MGX)